MedTrace Logo

GriCoVax Study in 4 Maternity Wards in the Ile-de-France Region

NCT04494581 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2020-07-31

No results posted yet for this study

Summary

Implementation of organizational adjustments can enhance involvement of healthcare teams in carrying out flu and pertussis vaccinations, and optimizing access to vaccines for women and their families. Pertussis vaccination of pregnant women is envisaged by the French Health Autority, considering that, given international experiences, vaccination during the second trimester of pregnancy is safe, effective, and would aim to protect babies during the first months of their life. Before considering such a recommendation in France, the acceptability of this strategy by pregnant women and health professionals must be considered.

Conditions

  • Pertussis Vaccine
  • Healthcare Worker Patient Transmission
  • Pregnant Women
  • Influenza Vaccination

Interventions

OTHER

questionnaire

Questionnaire survey

Sponsors & Collaborators

  • Agence Regionale de Sante d'Ile de France

    collaborator OTHER_GOV

  • National Agency of Public Health

    collaborator OTHER

  • Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux

    lead NETWORK

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-03
Primary Completion
2020-03-30
Completion
2020-03-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04494581 on ClinicalTrials.gov